CLX vs STRO · P/E 15, rev $7.10B vs rev $62.0M
The Clorox Company (CLX) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
The Clorox Company (CLX) is a household & personal products company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported CLX revenue for 2025-06-30 was $7.10B. Net income was $824.0M. Revenue was up 0.2% from 2024-06-30 to 2025-06-30. CLX currently screens at market cap $10.89B and trailing P/E 14.6.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
CLX currently screens at market cap $10.89B and trailing P/E 14.6. STRO currently screens at market cap $470.8M.
Not investment advice. Open the CLX and STRO stock pages for the full models.
Not investment advice.